2016•Value in HealthOpen access

Number Needed to Treat and Cost Per Clinically Meaningful Outcome of Enzalutamide and Abiraterone Acetate for The Treatment of Metastatic Castration-Resistant Prostate Cancer That Failed Androgen Deprivation Therapy in Brazil

AP Sasse, Gilberto De Lima Lopes Jr., V Teich, AP Fay, Mahzad Roostaei Hosein Abadi, NM Schultz, Stephen Doral Stefani

Open full text 0 citations

Abstract

This record does not include an abstract. Use the full-text link above if available.

About this research paper

What this paper is about

An abstract is not available in the OpenAlex record for this paper.

Why it matters

A significance statement is not available in the OpenAlex record.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Key concepts: Enzalutamide, Medicine, Abiraterone acetate, Prostate cancer, Number needed to treat, Oncology, Chemotherapy, Androgen deprivation therapy

Back to paper search Browse research topics Original source

Number Needed to Treat and Cost Per Clinically Meaningful Outcome of Enzalutamide and Abiraterone Acetate for The Treatment of Metastatic Castration-Resistant Prostate Cancer That Failed Androgen Deprivation Therapy in Brazil — Research Paper | ScholarLens